Header Logo

Connection

SETH LERNER to Urinary Bladder Neoplasms

Back to Details
This is a "connection" page, showing publications SETH LERNER has written about Urinary Bladder Neoplasms.
SETH LERNER
Connection Strength
37.209
Urinary Bladder Neoplasms
  1. Proteogenomic characterization unveils biomarkers associated with chemoresistance in muscle-invasive bladder cancer. Cell Rep Med. 2025 Aug 19; 6(8):102255.
    View in: PubMed
    Score: 0.663
  2. Standard or Extended Lymphadenectomy for Muscle-Invasive Bladder Cancer. N Engl J Med. 2024 Oct 03; 391(13):1206-1216.
    View in: PubMed
    Score: 0.626
  3. Association of Molecular Subtypes with Pathologic Response, PFS, and OS in a Phase II Study of COXEN with Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer. Clin Cancer Res. 2024 01 17; 30(2):444-449.
    View in: PubMed
    Score: 0.596
  4. Phase 2 Trial of Atezolizumab in Bacillus Calmette-Gu?rin-unresponsive High-risk Non-muscle-invasive Bladder Cancer: SWOG S1605. Eur Urol. 2023 12; 84(6):536-544.
    View in: PubMed
    Score: 0.579
  5. Poly (ADP-ribose) Polymerase Inhibition in Advanced Urothelial Carcinoma. JCO Precis Oncol. 2023 08; 7:e2300293.
    View in: PubMed
    Score: 0.577
  6. Long-term Outcomes from a Phase 2 Study of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer (SWOG S1314; NCT02177695). Eur Urol. 2023 09; 84(3):341-347.
    View in: PubMed
    Score: 0.574
  7. Evolving the surgical approach for bladder cancer - robotic versus open radical cystectomy. Nat Rev Urol. 2023 04; 20(4):203-204.
    View in: PubMed
    Score: 0.564
  8. Risk Stratification of Nonmuscle Invasive Bladder Cancer and Innovative Approaches to Management of Ta Low-Grade Tumors. J Clin Oncol. 2023 01 10; 41(2):163-166.
    View in: PubMed
    Score: 0.551
  9. Drug instillation in the management of urinary tract urothelial carcinoma. Curr Opin Urol. 2022 09 01; 32(5):531-535.
    View in: PubMed
    Score: 0.537
  10. Durability of Response to Primary Chemoablation of Low-Grade Upper Tract Urothelial Carcinoma Using UGN-101, a Mitomycin-Containing Reverse Thermal Gel: OLYMPUS Trial Final Report. J Urol. 2022 Apr; 207(4):779-788.
    View in: PubMed
    Score: 0.516
  11. Re: Identification of Differential Tumor Subtypes of T1 Bladder Cancer. Eur Urol. 2022 01; 81(1):118-119.
    View in: PubMed
    Score: 0.513
  12. Phase II multi-center trial of optical coherence tomography as an adjunct to white light cystoscopy for intravesical real time imaging and staging of bladder cancer. Urol Oncol. 2021 07; 39(7):434.e23-434.e29.
    View in: PubMed
    Score: 0.493
  13. Novel Thermo-Sensitive Hydrogel Therapy for Low-Grade Upper Tract Urothelial Carcinoma. J Urol. 2021 08; 206(2):191-193.
    View in: PubMed
    Score: 0.491
  14. Targeting barriers to wider use of trimodality therapy in localized muscle invasive bladder cancer. Urol Oncol. 2023 01; 41(1):35-38.
    View in: PubMed
    Score: 0.477
  15. Utility of lymphadenectomy in bladder cancer: where do we stand? Curr Opin Urol. 2020 05; 30(3):407-414.
    View in: PubMed
    Score: 0.461
  16. The Cancer Genome Atlas Expression Subtypes Stratify Response to Checkpoint Inhibition in Advanced Urothelial Cancer and Identify a Subset of Patients with High Survival Probability. Eur Urol. 2019 06; 75(6):961-964.
    View in: PubMed
    Score: 0.425
  17. What is the Standard of Care for Pelvic Lymphadenectomy Performed at the Time of Radical Cystectomy? Eur Urol. 2019 04; 75(4):612-614.
    View in: PubMed
    Score: 0.420
  18. SIU-ICUD consultation on bladder cancer: basic science. World J Urol. 2019 Jan; 37(1):15-29.
    View in: PubMed
    Score: 0.418
  19. Background and Update for S1602 "A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming with Intradermal BCG Before Intravesical Therapy for BCG-na?ve High-grade Non-muscle-invasive Bladder Cancer. Eur Urol Focus. 2018 07; 4(4):522-524.
    View in: PubMed
    Score: 0.411
  20. The Cancer Genome Atlas Project in Bladder Cancer. Cancer Treat Res. 2018; 175:259-271.
    View in: PubMed
    Score: 0.392
  21. Molecular Landscape of Non-Muscle Invasive Bladder Cancer. Cancer Cell. 2017 11 13; 32(5):550-551.
    View in: PubMed
    Score: 0.388
  22. Molecular Subtypes of Non-muscle Invasive Bladder Cancer. Cancer Cell. 2016 07 11; 30(1):1-3.
    View in: PubMed
    Score: 0.354
  23. Bladder cancer: ASCO endorses EAU muscle-invasive bladder cancer guidelines. Nat Rev Urol. 2016 08; 13(8):440-1.
    View in: PubMed
    Score: 0.353
  24. Editorial Comment. J Urol. 2016 Jan; 195(1):59.
    View in: PubMed
    Score: 0.338
  25. Variability in surgical quality in a phase III clinical trial of radical cystectomy in patients with organ-confined, node-negative urothelial carcinoma of the bladder. J Surg Oncol. 2015 Jun; 111(7):923-8.
    View in: PubMed
    Score: 0.325
  26. Significance of lymphovascular invasion in organ-confined, node-negative urothelial cancer of the bladder: data from the prospective p53-MVAC trial. BJU Int. 2015 Jul; 116(1):44-9.
    View in: PubMed
    Score: 0.323
  27. Potential role for targeted therapy in muscle-invasive bladder cancer: lessons from the cancer genome atlas and beyond. Urol Clin North Am. 2015 May; 42(2):201-15, viii.
    View in: PubMed
    Score: 0.322
  28. Targeted therapies for metastatic bladder cancer. J Urol. 2015 Jan; 193(1):8-9.
    View in: PubMed
    Score: 0.314
  29. New imaging techniques for nonmuscle invasive bladder cancer. Curr Opin Urol. 2014 Sep; 24(5):532-9.
    View in: PubMed
    Score: 0.311
  30. Novel endoscopic diagnosis for bladder cancer. Cancer. 2015 Jan 15; 121(2):169-78.
    View in: PubMed
    Score: 0.309
  31. Bladder cancer: Always consider extravesical sites when BCG fails. Nat Rev Urol. 2014 Jan; 11(1):11-2.
    View in: PubMed
    Score: 0.296
  32. Innovations in radical cystectomy and pelvic lymph node dissection. Semin Oncol. 2012 Oct; 39(5):573-82.
    View in: PubMed
    Score: 0.272
  33. Strategies to prevent progression of high-risk bladder cancer at initial diagnosis. Curr Opin Urol. 2012 Sep; 22(5):405-14.
    View in: PubMed
    Score: 0.271
  34. Urine survivin as a diagnostic biomarker for bladder cancer: a systematic review. BJU Int. 2012 Sep; 110(5):630-6.
    View in: PubMed
    Score: 0.261
  35. A randomized controlled trial of celecoxib to prevent recurrence of nonmuscle-invasive bladder cancer. Cancer Prev Res (Phila). 2011 Oct; 4(10):1580-9.
    View in: PubMed
    Score: 0.253
  36. Fluorescence and white light cystoscopy for detection of carcinoma in situ of the urinary bladder. Urol Oncol. 2012 May-Jun; 30(3):285-9.
    View in: PubMed
    Score: 0.244
  37. Editorial comment. J Urol. 2010 Jul; 184(1):79-80.
    View in: PubMed
    Score: 0.233
  38. BCAN Think Tank session 3: Prevention of bladder cancer. Urol Oncol. 2010 May-Jun; 28(3):338-42.
    View in: PubMed
    Score: 0.230
  39. Editorial comment. J Urol. 2010 Feb; 183(2):504.
    View in: PubMed
    Score: 0.224
  40. Innovations in endoscopic imaging for bladder cancer. Eur Urol. 2009 Dec; 56(6):920-2.
    View in: PubMed
    Score: 0.219
  41. Application of new technology in bladder cancer diagnosis and treatment. World J Urol. 2009 Jun; 27(3):301-7.
    View in: PubMed
    Score: 0.212
  42. Risk-adapted use of intravesical chemotherapy. BJU Int. 2008 Nov; 102(9 Pt B):1247-53.
    View in: PubMed
    Score: 0.208
  43. Prostatic biology, histologic patterns and clinical consequences of transitional cell carcinoma. Curr Opin Urol. 2008 Sep; 18(5):508-12.
    View in: PubMed
    Score: 0.205
  44. Pathologic assessment and clinical significance of prostatic involvement by transitional cell carcinoma and prostate cancer. Urol Oncol. 2008 Sep-Oct; 26(5):481-5.
    View in: PubMed
    Score: 0.205
  45. Occupational risk factors. Scand J Urol Nephrol Suppl. 2008 Sep; (218):58-63.
    View in: PubMed
    Score: 0.205
  46. Neoadjuvant chemotherapy preceding cystectomy for bladder cancer. Expert Opin Pharmacother. 2008 Aug; 9(11):1885-93.
    View in: PubMed
    Score: 0.204
  47. Optical coherence tomography as an adjunct to white light cystoscopy for intravesical real-time imaging and staging of bladder cancer. Urology. 2008 Jul; 72(1):133-7.
    View in: PubMed
    Score: 0.203
  48. Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model. Urol Oncol. 2009 Jul-Aug; 27(4):391-9.
    View in: PubMed
    Score: 0.202
  49. Failure to achieve a complete response to induction BCG therapy is associated with increased risk of disease worsening and death in patients with high risk non-muscle invasive bladder cancer. Urol Oncol. 2009 Mar-Apr; 27(2):155-9.
    View in: PubMed
    Score: 0.198
  50. Molecular markers in bladder cancer. Curr Opin Urol. 2008 Jan; 18(1):1-8.
    View in: PubMed
    Score: 0.196
  51. Editorial comment on: Sentinel lymph node mapping of invasive urinary bladder cancer in animal models using invisible light. Eur Urol. 2007 Dec; 52(6):1708-9.
    View in: PubMed
    Score: 0.195
  52. Neoadjuvant chemotherapy for bladder cancer. Oncology (Williston Park). 2007 Dec; 21(14):1673-81; discussion 1686-8, 1691, 1694.
    View in: PubMed
    Score: 0.195
  53. Prostatic transitional cell carcinoma: pathologic features and clinical management. Expert Rev Anticancer Ther. 2007 Aug; 7(8):1155-62.
    View in: PubMed
    Score: 0.190
  54. The use and abuse of data: nomograms and talking to patients about clinical medicine. Urol Oncol. 2007 Jul-Aug; 25(4):333-7.
    View in: PubMed
    Score: 0.189
  55. Patterns of recurrence and outcomes following induction bacillus Calmette-Guerin for high risk Ta, T1 bladder cancer. J Urol. 2007 May; 177(5):1727-31.
    View in: PubMed
    Score: 0.187
  56. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. J Urol. 2006 Dec; 176(6 Pt 1):2414-22; discussion 2422.
    View in: PubMed
    Score: 0.182
  57. Chemoprevention of bladder cancer. World J Urol. 2006 Nov; 24(5):445-72.
    View in: PubMed
    Score: 0.181
  58. Nomogram for predicting disease recurrence after radical cystectomy for transitional cell carcinoma of the bladder. J Urol. 2006 Oct; 176(4 Pt 1):1354-61; discussion 1361-2.
    View in: PubMed
    Score: 0.180
  59. Treatment of high-risk, non-muscle-invasive bladder cancer. Nat Clin Pract Urol. 2006 Aug; 3(8):398-9.
    View in: PubMed
    Score: 0.178
  60. Advances in diagnosis and therapy of transitional cell carcinoma of the bladder. Urol Oncol. 2006 Jul-Aug; 24(4):324-5.
    View in: PubMed
    Score: 0.177
  61. Precystectomy nomogram for prediction of advanced bladder cancer stage. Eur Urol. 2006 Dec; 50(6):1254-60; discussion 1261-2.
    View in: PubMed
    Score: 0.176
  62. Expression of estrogen receptors-alpha and -beta in bladder cancer cell lines and human bladder tumor tissue. Cancer. 2006 Jun 15; 106(12):2610-6.
    View in: PubMed
    Score: 0.176
  63. Combining surgery and chemotherapy for invasive bladder cancer: current and future directions. Expert Rev Anticancer Ther. 2006 Feb; 6(2):281-91.
    View in: PubMed
    Score: 0.172
  64. Cisplatin-ineligible patients with muscle-invasive bladder cancer demonstrate poor long-term survival following immediate radical cystectomy. BJU Int. 2026 Jan; 137(1):181-188.
    View in: PubMed
    Score: 0.167
  65. End Points for the Next-Generation Bladder-Sparing Perioperative Trials for Patients With Muscle-Invasive Bladder Cancer. J Clin Oncol. 2025 Nov 10; 43(32):3536-3544.
    View in: PubMed
    Score: 0.167
  66. Low-grade non-muscle-invasive bladder cancer: molecular landscape, treatment strategies and emerging therapies. Nat Rev Urol. 2025 Dec; 22(12):846-861.
    View in: PubMed
    Score: 0.167
  67. Loss of coxsackie and adenovirus receptor expression is associated with features of aggressive bladder cancer. Urology. 2005 Aug; 66(2):441-6.
    View in: PubMed
    Score: 0.166
  68. Patients with unusual bladder malignancies and a rare cause of splenomegaly. Case 1. Small-cell carcinoma of the urinary bladder. J Clin Oncol. 2005 Jul 01; 23(19):4458-9.
    View in: PubMed
    Score: 0.165
  69. Patients with unusual bladder malignancies and a rare cause of splenomegaly. Case 2. Rhabdomyosarcoma of the urinary bladder in an adult. J Clin Oncol. 2005 Jul 01; 23(19):4459-60.
    View in: PubMed
    Score: 0.165
  70. Bladder cancer clinical trials. Urol Oncol. 2005 Jul-Aug; 23(4):275-9.
    View in: PubMed
    Score: 0.165
  71. Urine Tumor DNA to Stratify the Risk of Recurrence in Patients Treated with Atezolizumab for Bacillus Calmette-Gu?rin-unresponsive Non-muscle-invasive Bladder Cancer. Eur Urol. 2025 Nov; 88(5):430-434.
    View in: PubMed
    Score: 0.163
  72. Urinary levels of soluble e-cadherin in the detection of transitional cell carcinoma of the urinary bladder. Eur Urol. 2005 Jul; 48(1):69-76.
    View in: PubMed
    Score: 0.161
  73. Impact of Tumor Stage on Oncologic Outcomes of High-grade Bacillus Calmette-Gu?rin Unresponsive Non-muscle-invasive Bladder Cancer Undergoing Bladder-sparing Therapies. Eur Urol Focus. 2025 May; 11(3):448-455.
    View in: PubMed
    Score: 0.160
  74. The Financial Burden of Localized and Metastatic Bladder Cancer. Eur Urol. 2025 May; 87(5):536-550.
    View in: PubMed
    Score: 0.159
  75. Oncologic Outcomes of Sequential Intravesical Gemcitabine and Docetaxel Compared with Bacillus Calmette-Gu?rin in Patients with Bacillus Calmette-Gu?rin-Unresponsive Non-Muscle Invasive Bladder Cancer. Eur Urol Oncol. 2025 Apr; 8(2):469-476.
    View in: PubMed
    Score: 0.159
  76. DNA Damage Response Alterations Predict for Neoadjuvant Chemotherapy Sensitivity in Muscle-Invasive Bladder Cancer: A Correlative Analysis of the SWOG S1314 Trial. JCO Precis Oncol. 2024 Nov; 8:e2400287.
    View in: PubMed
    Score: 0.157
  77. Alternatives to cytology in the management of non-muscle invasive bladder cancer. Curr Treat Options Oncol. 2004 Oct; 5(5):377-89.
    View in: PubMed
    Score: 0.156
  78. Mitochondrial reprogramming by activating OXPHOS via glutamine metabolism in African American patients with bladder cancer. JCI Insight. 2024 Sep 10; 9(17).
    View in: PubMed
    Score: 0.156
  79. Long-term outcomes of bladder-sparing therapy vs radical cystectomy in BCG-unresponsive non-muscle-invasive bladder cancer. BJU Int. 2025 Feb; 135(2):260-268.
    View in: PubMed
    Score: 0.155
  80. Bladder-sparing Therapy for Bacillus Calmette-Gu?rin-unresponsive Non-muscle-invasive Bladder Cancer: International Bladder Cancer Group Recommendations for Optimal Sequencing and Patient Selection. Eur Urol. 2024 Dec; 86(6):516-527.
    View in: PubMed
    Score: 0.155
  81. Correlative Analysis of ATM, RB1, ERCC2, and FANCC Mutations and Pathologic Complete Response After Neoadjuvant Chemotherapy in Patients with Muscle-invasive Bladder Cancer: Results from the SWOG S1314 Trial. Eur Urol. 2024 Oct; 86(4):297-300.
    View in: PubMed
    Score: 0.154
  82. Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Gu?rin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial. J Urol. 2024 Jul; 212(1):74-86.
    View in: PubMed
    Score: 0.152
  83. Stage specific lymph node metastasis mapping in radical cystectomy specimens. J Urol. 2004 May; 171(5):1830-4.
    View in: PubMed
    Score: 0.152
  84. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer. J Clin Oncol. 2004 Mar 15; 22(6):1014-24.
    View in: PubMed
    Score: 0.150
  85. The IL6/JAK/STAT3 signaling axis is a therapeutic vulnerability in SMARCB1-deficient bladder cancer. Nat Commun. 2024 Feb 14; 15(1):1373.
    View in: PubMed
    Score: 0.150
  86. Urine detection of survivin is a sensitive marker for the noninvasive diagnosis of bladder cancer. J Urol. 2004 Feb; 171(2 Pt 1):626-30.
    View in: PubMed
    Score: 0.149
  87. Granulocyte colony-stimulating factor receptor signals for beta1-integrin expression and adhesion in bladder cancer. Urology. 2004 Jan; 63(1):177-83.
    View in: PubMed
    Score: 0.148
  88. The addition of urinary urokinase-type plasminogen activator to urinary nuclear matrix protein 22 and cytology improves the detection of bladder cancer. J Urol. 2003 Dec; 170(6 Pt 1):2244-7.
    View in: PubMed
    Score: 0.148
  89. Preoperative plasma soluble E-cadherin predicts metastases to lymph nodes and prognosis in patients undergoing radical cystectomy. J Urol. 2003 Dec; 170(6 Pt 1):2248-52.
    View in: PubMed
    Score: 0.148
  90. Definitions, End Points, and Clinical Trial Designs for Bladder Cancer: Recommendations From the Society for Immunotherapy of Cancer and the International Bladder Cancer Group. J Clin Oncol. 2023 12 10; 41(35):5437-5447.
    View in: PubMed
    Score: 0.146
  91. Correlation of cyclooxygenase-2 expression with molecular markers, pathological features and clinical outcome of transitional cell carcinoma of the bladder. J Urol. 2003 Sep; 170(3):985-9.
    View in: PubMed
    Score: 0.145
  92. Perioperative chemotherapy in locally advanced bladder cancer. Lancet. 2003 Jun 07; 361(9373):1922-3.
    View in: PubMed
    Score: 0.143
  93. Association of p53 and p21 expression with clinical outcome in patients with carcinoma in situ of the urinary bladder. Urology. 2003 Jun; 61(6):1140-5.
    View in: PubMed
    Score: 0.143
  94. Epidemiology of Bladder Cancer in 2023: A Systematic Review of Risk Factors. Eur Urol. 2023 08; 84(2):176-190.
    View in: PubMed
    Score: 0.142
  95. Combination of adenovirus-mediated thymidine kinase gene therapy with cytotoxic chemotherapy in bladder cancer in vitro. Urol Oncol. 2003 May-Jun; 21(3):197-205.
    View in: PubMed
    Score: 0.142
  96. Cell-free DNA Methylation as a Predictive Biomarker of Response to Neoadjuvant Chemotherapy for Patients with Muscle-invasive Bladder Cancer in SWOG S1314. Eur Urol Oncol. 2023 10; 6(5):516-524.
    View in: PubMed
    Score: 0.141
  97. Circulating and urinary tumour DNA in urothelial carcinoma?- upper tract, lower tract and metastatic disease. Nat Rev Urol. 2023 07; 20(7):406-419.
    View in: PubMed
    Score: 0.141
  98. Cyclooxygenase-2 is highly expressed in carcinoma in situ and T1 transitional cell carcinoma of the bladder. J Urol. 2003 Mar; 169(3):938-42.
    View in: PubMed
    Score: 0.140
  99. Urinary levels of urokinase-type plasminogen activator and its receptor in the detection of bladder carcinoma. Cancer. 2002 Dec 15; 95(12):2494-9.
    View in: PubMed
    Score: 0.138
  100. Targeting FGFR3 alterations with adjuvant infigratinib in invasive urothelial carcinoma: the phase III PROOF 302 trial. Future Oncol. 2022 Jul; 18(21):2599-2614.
    View in: PubMed
    Score: 0.133
  101. Preoperative plasma levels of interleukin-6 and its soluble receptor predict disease recurrence and survival of patients with bladder cancer. J Urol. 2002 Mar; 167(3):1475-81.
    View in: PubMed
    Score: 0.131
  102. International Bladder Cancer Group Consensus Statement on Clinical Trial Design for Patients with Bacillus Calmette-Gu?rin-exposed High-risk Non-muscle-invasive Bladder Cancer. Eur Urol. 2022 07; 82(1):34-46.
    View in: PubMed
    Score: 0.129
  103. Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non-muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical Trial. Eur Urol. 2022 03; 81(3):223-228.
    View in: PubMed
    Score: 0.129
  104. Predictive value of expression of transforming growth factor-beta(1) and its receptors in transitional cell carcinoma of the urinary bladder. Cancer. 2001 Sep 15; 92(6):1475-83.
    View in: PubMed
    Score: 0.127
  105. Refining neoadjuvant therapy clinical trial design for muscle-invasive bladder cancer before cystectomy: a joint US Food and Drug Administration and Bladder Cancer Advocacy Network workshop. Nat Rev Urol. 2022 01; 19(1):37-46.
    View in: PubMed
    Score: 0.127
  106. Correlation of immunohistochemical molecular staging of bladder biopsies and radical cystectomy specimens. Int J Radiat Oncol Biol Phys. 2001 Sep 01; 51(1):16-22.
    View in: PubMed
    Score: 0.126
  107. E-cadherin immunostaining of bladder transitional cell carcinoma, carcinoma in situ and lymph node metastases with long-term followup. J Urol. 2001 May; 165(5):1473-9.
    View in: PubMed
    Score: 0.123
  108. Surgical challenges and considerations in Tri-modal therapy for muscle invasive bladder cancer. Urol Oncol. 2022 10; 40(10):442-450.
    View in: PubMed
    Score: 0.122
  109. A Randomized Phase II Study of Coexpression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Bladder Cancer (SWOG S1314; NCT02177695). Clin Cancer Res. 2021 05 01; 27(9):2435-2441.
    View in: PubMed
    Score: 0.122
  110. Rebuilding the lower urinary tract after cystectomy: a roadmap for patient selection and counseling. Semin Urol Oncol. 2001 Feb; 19(1):24-36.
    View in: PubMed
    Score: 0.121
  111. The Who, What, When, Where, and Why of Bacillus Calmette-Gu?rin-unresponsive Bladder Cancer. Eur Urol. 2021 04; 79(4):437-439.
    View in: PubMed
    Score: 0.121
  112. E-cadherin expression predicts clinical outcome in carcinoma in situ of the urinary bladder. Urology. 2001 Jan; 57(1):60-5.
    View in: PubMed
    Score: 0.121
  113. Glut 1 expression in transitional cell carcinoma of the urinary bladder is associated with poor patient survival. Anticancer Res. 2001 Jan-Feb; 21(1B):575-8.
    View in: PubMed
    Score: 0.121
  114. Genetic Differences Between Bladder and Upper Urinary Tract Carcinoma: Implications for Therapy. Eur Urol Oncol. 2021 04; 4(2):170-179.
    View in: PubMed
    Score: 0.121
  115. Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. Lancet Oncol. 2021 01; 22(1):107-117.
    View in: PubMed
    Score: 0.120
  116. Prognostic value of P53 nuclear accumulation and histopathologic features in T1 transitional cell carcinoma of the urinary bladder. Urology. 2000 Nov 01; 56(5):735-40.
    View in: PubMed
    Score: 0.119
  117. In vivo adenovirus-mediated suicide gene therapy of orthotopic bladder cancer. Mol Ther. 2000 Sep; 2(3):211-7.
    View in: PubMed
    Score: 0.118
  118. Adenovirus-mediated suicide gene therapy for bladder cancer: comparison of the cytomegalovirus- and Rous sarcoma virus-promoter. Anticancer Res. 2000 Sep-Oct; 20(5A):2811-6.
    View in: PubMed
    Score: 0.118
  119. Adenovirus-mediated combination suicide and cytokine gene therapy for bladder cancer. Anticancer Res. 2000 May-Jun; 20(3A):1359-65.
    View in: PubMed
    Score: 0.115
  120. Evidence-based Assessment of Current and Emerging Bladder-sparing Therapies for Non-muscle-invasive Bladder Cancer After Bacillus Calmette-Guerin Therapy: A Systematic Review and Meta-analysis. Eur Urol Oncol. 2020 06; 3(3):318-340.
    View in: PubMed
    Score: 0.114
  121. Transurethral Resection of Bladder Tumour: The Neglected Procedure in the Technology Race in Bladder Cancer. Eur Urol. 2020 06; 77(6):669-670.
    View in: PubMed
    Score: 0.114
  122. Reply To Kenneth B. Yatai, Mark J. Dunning, Dennis Wang. Consensus Genomic Subtypes of Muscle-invasive Bladder Cancer: A Step in the Right Direction but Still a Long Way To Go. Eur Urol 2020;77:434-5. Eur Urol. 2020 04; 77(4):436-438.
    View in: PubMed
    Score: 0.113
  123. Eligibility and Radiologic Assessment in Adjuvant Clinical Trials in Bladder Cancer. JAMA Oncol. 2019 12 01; 5(12):1790-1798.
    View in: PubMed
    Score: 0.112
  124. DNA methylation patterns in bladder tumors of African American patients point to distinct alterations in xenobiotic metabolism. Carcinogenesis. 2019 11 25; 40(11):1332-1340.
    View in: PubMed
    Score: 0.112
  125. Adaptive Immune Resistance to Intravesical BCG in Non-Muscle Invasive Bladder Cancer: Implications for Prospective BCG-Unresponsive Trials. Clin Cancer Res. 2020 02 15; 26(4):882-891.
    View in: PubMed
    Score: 0.111
  126. A Consensus Molecular Classification of Muscle-invasive Bladder Cancer. Eur Urol. 2020 04; 77(4):420-433.
    View in: PubMed
    Score: 0.110
  127. Decreased expression of transforming growth factor beta receptor type I is associated with poor prognosis in bladder transitional cell carcinoma patients. Clin Cancer Res. 1999 Sep; 5(9):2520-5.
    View in: PubMed
    Score: 0.110
  128. Molecular Subtyping of Clinically Localized Urothelial Carcinoma Reveals Lower Rates of Pathological Upstaging at Radical Cystectomy Among Luminal Tumors. Eur Urol. 2019 08; 76(2):200-206.
    View in: PubMed
    Score: 0.108
  129. Multi-omics Integration Analysis Robustly Predicts High-Grade Patient Survival and Identifies CPT1B Effect on Fatty Acid Metabolism in Bladder Cancer. Clin Cancer Res. 2019 06 15; 25(12):3689-3701.
    View in: PubMed
    Score: 0.106
  130. Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting And Data System). Eur Urol. 2018 09; 74(3):294-306.
    View in: PubMed
    Score: 0.100
  131. Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-Grade Non-Muscle-Invasive Bladder Cancer on Tumor Recurrence: SWOG S0337 Randomized Clinical Trial. JAMA. 2018 05 08; 319(18):1880-1888.
    View in: PubMed
    Score: 0.100
  132. Is folic acid safe for non-muscle-invasive bladder cancer patients? An evidence-based cohort study. Am J Clin Nutr. 2018 02 01; 107(2):208-216.
    View in: PubMed
    Score: 0.099
  133. Dietary patterns and risk of recurrence and progression in non-muscle-invasive bladder cancer. Int J Cancer. 2018 05 01; 142(9):1797-1804.
    View in: PubMed
    Score: 0.098
  134. Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. Cell. 2017 Oct 19; 171(3):540-556.e25.
    View in: PubMed
    Score: 0.096
  135. Current status of gene therapy for prostate and bladder cancer. Int J Urol. 1997 Sep; 4(5):435-40.
    View in: PubMed
    Score: 0.096
  136. Tobacco-Specific Carcinogens Induce Hypermethylation, DNA Adducts, and DNA Damage in Bladder Cancer. Cancer Prev Res (Phila). 2017 Oct; 10(10):588-597.
    View in: PubMed
    Score: 0.096
  137. Intravesical rAd-IFNa/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin-Refractory or Relapsed Non-Muscle-Invasive Bladder Cancer: A Phase II Randomized Study. J Clin Oncol. 2017 Oct 20; 35(30):3410-3416.
    View in: PubMed
    Score: 0.096
  138. Treatment of Nonmetastatic Muscle-Invasive Bladder Cancer: American Urological Association/American Society of Clinical Oncology/American Society for Radiation Oncology/Society of Urologic Oncology Clinical Practice Guideline Summary. J Oncol Pract. 2017 09; 13(9):621-625.
    View in: PubMed
    Score: 0.095
  139. Comprehensive Genomic Characterization of Upper Tract Urothelial Carcinoma. Eur Urol. 2017 10; 72(4):641-649.
    View in: PubMed
    Score: 0.094
  140. Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline. J Urol. 2017 09; 198(3):552-559.
    View in: PubMed
    Score: 0.093
  141. Distinct Lipidomic Landscapes Associated with Clinical Stages of Urothelial Cancer of the Bladder. Eur Urol Focus. 2018 12; 4(6):907-915.
    View in: PubMed
    Score: 0.093
  142. Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy. Eur Urol. 2017 10; 72(4):544-554.
    View in: PubMed
    Score: 0.093
  143. Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in the Cancer Genome Atlas Dataset. Eur Urol. 2017 09; 72(3):354-365.
    View in: PubMed
    Score: 0.093
  144. Adenovirus-mediated suicide gene therapy for experimental bladder cancer. Urology. 1997 Feb; 49(2):173-80.
    View in: PubMed
    Score: 0.092
  145. Aurora Kinase A is a Biomarker for Bladder Cancer Detection and Contributes to its Aggressive Behavior. Sci Rep. 2017 01 19; 7:40714.
    View in: PubMed
    Score: 0.092
  146. Bacillus Calmette-Gu?rin Manufacturing and SWOG S1602 Intergroup Clinical Trial. J Urol. 2017 03; 197(3 Pt 1):538-540.
    View in: PubMed
    Score: 0.091
  147. Positive association of collagen type I with non-muscle invasive bladder cancer progression. Oncotarget. 2016 Dec 13; 7(50):82609-82619.
    View in: PubMed
    Score: 0.091
  148. Neutrophil-to-lymphocyte ratio as a bladder cancer biomarker: Assessing prognostic and predictive value in SWOG 8710. Cancer. 2017 Mar 01; 123(5):794-801.
    View in: PubMed
    Score: 0.090
  149. Diagnostic and Prognostic Markers in Bladder Cancer. Dis Markers. 2016; 2016:2425091.
    View in: PubMed
    Score: 0.090
  150. Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC). World J Urol. 2017 Mar; 35(3):379-387.
    View in: PubMed
    Score: 0.089
  151. Bladder cancer. Lancet. 2016 12 03; 388(10061):2796-2810.
    View in: PubMed
    Score: 0.088
  152. Prognostic Significance of Neutrophilic Infiltration in Benign Lymph Nodes in Patients with Muscle-invasive Bladder Cancer. Eur Urol Focus. 2017 02; 3(1):130-135.
    View in: PubMed
    Score: 0.087
  153. The case for salvage cystectomy after pelvic radiation. Minerva Urol Nefrol. 2016 Apr; 68(2):161-71.
    View in: PubMed
    Score: 0.086
  154. Validating a Local Failure Risk Stratification for Use in Prospective Studies of Adjuvant Radiation Therapy for Bladder Cancer. Int J Radiat Oncol Biol Phys. 2016 06 01; 95(2):703-6.
    View in: PubMed
    Score: 0.086
  155. Integrative Pathway Analysis of Metabolic Signature in Bladder Cancer: A Linkage to The Cancer Genome Atlas Project and Prediction of Survival. J Urol. 2016 06; 195(6):1911-9.
    View in: PubMed
    Score: 0.086
  156. Invasive Bladder Cancer: Genomic Insights and Therapeutic Promise. Clin Cancer Res. 2015 Oct 15; 21(20):4514-24.
    View in: PubMed
    Score: 0.084
  157. Neoadjuvant dasatinib for muscle-invasive bladder cancer with tissue analysis of biologic activity. Urol Oncol. 2016 Jan; 34(1):4.e11-7.
    View in: PubMed
    Score: 0.083
  158. External Validation of Bladder Cancer Predictive Nomograms for Recurrence, Cancer-Free Survival and Overall Survival following Radical Cystectomy. J Urol. 2016 Feb; 195(2):283-9.
    View in: PubMed
    Score: 0.083
  159. The role of surgery in the management of pediatric pelvic rhabdomyosarcoma. J Urol. 1995 Aug; 154(2 Pt 1):540-5.
    View in: PubMed
    Score: 0.083
  160. New trends in the surgical management of invasive bladder cancer. Hematol Oncol Clin North Am. 2015 Apr; 29(2):253-69, viii.
    View in: PubMed
    Score: 0.081
  161. Prognostic and Prediction Tools in Bladder Cancer: A Comprehensive Review of the Literature. Eur Urol. 2015 Aug; 68(2):238-53.
    View in: PubMed
    Score: 0.080
  162. Blocking PGE2-induced tumour repopulation abrogates bladder cancer chemoresistance. Nature. 2015 Jan 08; 517(7533):209-13.
    View in: PubMed
    Score: 0.079
  163. Educational opportunities in bladder cancer: increasing cystoscopic adherence and the availability of smoking-cessation programs. J Cancer Educ. 2014 Dec; 29(4):739-45.
    View in: PubMed
    Score: 0.079
  164. Novel neoadjuvant therapy paradigms for bladder cancer: results from the National Cancer Center Institute Forum. Urol Oncol. 2014 Nov; 32(8):1108-15.
    View in: PubMed
    Score: 0.079
  165. Usefulness of transurethral biopsy for staging the prostatic urethra before radical cystectomy. J Urol. 2015 Jan; 193(1):58-63.
    View in: PubMed
    Score: 0.077
  166. Reply by the authors. Urology. 2014 Aug; 84(2):495-6.
    View in: PubMed
    Score: 0.077
  167. The preclinical activity of lenalidomide in indolent urothelial carcinoma. Anticancer Res. 2014 Jul; 34(7):3383-9.
    View in: PubMed
    Score: 0.077
  168. Female gender is associated with a worse survival after radical cystectomy for urothelial carcinoma of the bladder: a competing risk analysis. Urology. 2014 Apr; 83(4):863-7.
    View in: PubMed
    Score: 0.075
  169. Optimizing bladder cancer locoregional failure risk stratification after radical cystectomy using SWOG 8710. Cancer. 2014 Apr 15; 120(8):1272-80.
    View in: PubMed
    Score: 0.074
  170. Urinary diversion after radical cystectomy for bladder cancer: options, patient selection, and outcomes. BJU Int. 2014 Jan; 113(1):11-23.
    View in: PubMed
    Score: 0.074
  171. Clinical trial design for the development of new therapies for nonmuscle-invasive bladder cancer: report of a Food and Drug Administration and American Urological Association public workshop. Urology. 2014 Feb; 83(2):262-4.
    View in: PubMed
    Score: 0.074
  172. Genome-wide association study identifies multiple loci associated with bladder cancer risk. Hum Mol Genet. 2014 Mar 01; 23(5):1387-98.
    View in: PubMed
    Score: 0.073
  173. Lymphadenectomy for bladder cancer at the time of radical cystectomy. Eur Urol. 2013 Aug; 64(2):266-76.
    View in: PubMed
    Score: 0.071
  174. SWOG S0353: Phase II trial of intravesical gemcitabine in patients with nonmuscle invasive bladder cancer and recurrence after 2 prior courses of intravesical bacillus Calmette-Gu?rin. J Urol. 2013 Oct; 190(4):1200-4.
    View in: PubMed
    Score: 0.071
  175. The rationale for en bloc pelvic lymph node dissection for bladder cancer patients with nodal metastases: long-term results. J Urol. 1993 Apr; 149(4):758-64; discussion 764-5.
    View in: PubMed
    Score: 0.070
  176. Critical analysis of contemporary clinical research in muscle-invasive and metastatic urothelial cancer: a report from the Bladder Cancer Advocacy Network Clinical Trials Working Group. Cancer. 2013 Jun 01; 119(11):1994-8.
    View in: PubMed
    Score: 0.070
  177. Gemcitabine, Cisplatin, and sunitinib for metastatic urothelial carcinoma and as preoperative therapy for muscle-invasive bladder cancer. Clin Genitourin Cancer. 2013 Jun; 11(2):175-81.
    View in: PubMed
    Score: 0.069
  178. Lymphovascular invasion is independently associated with bladder cancer recurrence and survival in patients with final stage T1 disease and negative lymph nodes after radical cystectomy. BJU Int. 2013 Jun; 111(8):1215-21.
    View in: PubMed
    Score: 0.069
  179. Radical cystectomy in regionally advanced bladder cancer. Urol Clin North Am. 1992 Nov; 19(4):713-23.
    View in: PubMed
    Score: 0.068
  180. A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer. J Urol. 2012 Dec; 188(6):2391-7.
    View in: PubMed
    Score: 0.068
  181. Raloxifene inhibits growth of RT4 urothelial carcinoma cells via estrogen receptor-dependent induction of apoptosis and inhibition of proliferation. Horm Cancer. 2013 Feb; 4(1):24-35.
    View in: PubMed
    Score: 0.068
  182. ICUD-EAU International Consultation on Bladder Cancer 2012: Radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder. Eur Urol. 2013 Jan; 63(1):45-57.
    View in: PubMed
    Score: 0.067
  183. A systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol. 2012 Sep; 62(3):523-33.
    View in: PubMed
    Score: 0.067
  184. Three differentiation states risk-stratify bladder cancer into distinct subtypes. Proc Natl Acad Sci U S A. 2012 Feb 07; 109(6):2078-83.
    View in: PubMed
    Score: 0.065
  185. A genome-wide association study of bladder cancer identifies a new susceptibility locus within SLC14A1, a urea transporter gene on chromosome 18q12.3. Hum Mol Genet. 2011 Nov 01; 20(21):4282-9.
    View in: PubMed
    Score: 0.063
  186. Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status. J Clin Oncol. 2011 Sep 01; 29(25):3443-9.
    View in: PubMed
    Score: 0.063
  187. A conventional preclinical schedule of cisplatin is more effective than a metronomic frequent bolus schedule for urothelial carcinoma. Urol Oncol. 2013 Feb; 31(2):234-40.
    View in: PubMed
    Score: 0.062
  188. Critical analysis and validation of lymph node density as prognostic variable in urothelial carcinoma of bladder. Urol Oncol. 2013 May; 31(4):480-6.
    View in: PubMed
    Score: 0.061
  189. Prognostic risk stratification of pathological stage T3N0 bladder cancer after radical cystectomy. J Urol. 2011 Apr; 185(4):1216-21.
    View in: PubMed
    Score: 0.061
  190. Disease-free survival at 2 or 3 years correlates with 5-year overall survival of patients undergoing radical cystectomy for muscle invasive bladder cancer. J Urol. 2011 Feb; 185(2):456-61.
    View in: PubMed
    Score: 0.060
  191. Prognostic risk stratification of pathological stage T2N0 bladder cancer after radical cystectomy. BJU Int. 2011 Sep; 108(5):687-92.
    View in: PubMed
    Score: 0.060
  192. Stage pT0 at radical cystectomy confers improved survival: an international study of 4,430 patients. J Urol. 2010 Sep; 184(3):888-94.
    View in: PubMed
    Score: 0.059
  193. The effectiveness of off-protocol adjuvant chemotherapy for patients with urothelial carcinoma of the urinary bladder. Clin Cancer Res. 2010 Sep 01; 16(17):4461-7.
    View in: PubMed
    Score: 0.058
  194. Soft tissue surgical margin status is a powerful predictor of outcomes after radical cystectomy: a multicenter study of more than 4,400 patients. J Urol. 2010 Jun; 183(6):2165-70.
    View in: PubMed
    Score: 0.058
  195. A critical analysis of orthotopic bladder substitutes in adult patients with bladder cancer: is there a perfect solution? Eur Urol. 2010 Sep; 58(3):374-83.
    View in: PubMed
    Score: 0.058
  196. Characteristics and outcomes of patients with clinical carcinoma in situ only treated with radical cystectomy: an international study of 243 patients. J Urol. 2010 May; 183(5):1757-63.
    View in: PubMed
    Score: 0.057
  197. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in liver, bladder, cervical, and gastric cancers. Clin Chem. 2010 Jun; 56(6):e1-48.
    View in: PubMed
    Score: 0.057
  198. Prevention and management of complications following radical cystectomy for bladder cancer. Eur Urol. 2010 Jun; 57(6):983-1001.
    View in: PubMed
    Score: 0.057
  199. Accuracy of the extent of bladder cancer nodal metastases found at pelvic lymphadenectomy at the time of cystectomy: relation to primary tumor stage. Urol Int. 2010; 84(1):14-22.
    View in: PubMed
    Score: 0.057
  200. International validation of the prognostic value of lymphovascular invasion in patients treated with radical cystectomy. BJU Int. 2010 May; 105(10):1402-12.
    View in: PubMed
    Score: 0.057
  201. Combination of multiple molecular markers can improve prognostication in patients with locally advanced and lymph node positive bladder cancer. J Urol. 2010 Jan; 183(1):68-75.
    View in: PubMed
    Score: 0.056
  202. Characteristics and outcomes of patients with pT4 urothelial carcinoma at radical cystectomy: a retrospective international study of 583 patients. J Urol. 2010 Jan; 183(1):87-93.
    View in: PubMed
    Score: 0.056
  203. Bladder cancer detection, treatment and outcomes: opportunities and challenges. Urology. 2010 Feb; 75(2):334-9.
    View in: PubMed
    Score: 0.056
  204. Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy. Cancer. 2009 Sep 15; 115(18):4104-9.
    View in: PubMed
    Score: 0.055
  205. Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort. Eur Urol. 2010 Feb; 57(2):300-9.
    View in: PubMed
    Score: 0.055
  206. p53 expression in patients with advanced urothelial cancer of the urinary bladder. BJU Int. 2010 Feb; 105(4):489-95.
    View in: PubMed
    Score: 0.055
  207. p53 predictive value for pT1-2 N0 disease at radical cystectomy. J Urol. 2009 Sep; 182(3):907-13.
    View in: PubMed
    Score: 0.054
  208. Residual pathological stage at radical cystectomy significantly impacts outcomes for initial T2N0 bladder cancer. J Urol. 2009 Aug; 182(2):459-65; discussion 465.
    View in: PubMed
    Score: 0.054
  209. Multi-institutional validation of the predictive value of Ki-67 labeling index in patients with urinary bladder cancer. J Natl Cancer Inst. 2009 Jan 21; 101(2):114-9.
    View in: PubMed
    Score: 0.053
  210. Assessing the minimum number of lymph nodes needed at radical cystectomy in patients with bladder cancer. BJU Int. 2009 May; 103(10):1359-62.
    View in: PubMed
    Score: 0.052
  211. Bladder cancer today. BJU Int. 2008 Nov; 102(9 Pt B):1203.
    View in: PubMed
    Score: 0.052
  212. Adjuvant chemotherapy for bladder cancer does not alter cancer-specific survival after cystectomy in a matched case-control study. BJU Int. 2008 Jun; 101(11):1356-61.
    View in: PubMed
    Score: 0.050
  213. Safety and side effects of immediate instillation of apaziquone following transurethral resection in patients with nonmuscle invasive bladder cancer. J Urol. 2008 Jul; 180(1):116-20.
    View in: PubMed
    Score: 0.050
  214. Outcomes of patients with clinical T1 grade 3 urothelial cell bladder carcinoma treated with radical cystectomy. Urology. 2008 Feb; 71(2):302-7.
    View in: PubMed
    Score: 0.049
  215. Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy. Cancer. 2008 Jan 15; 112(2):315-25.
    View in: PubMed
    Score: 0.049
  216. Phase III prevention trial of fenretinide in patients with resected non-muscle-invasive bladder cancer. Clin Cancer Res. 2008 Jan 01; 14(1):224-9.
    View in: PubMed
    Score: 0.049
  217. Macroscopic, but not microscopic, perivesical fat invasion at radical cystectomy is an adverse predictor of recurrence and survival. BJU Int. 2008 Feb; 101(4):450-4.
    View in: PubMed
    Score: 0.048
  218. A delay in radical cystectomy of >3 months is not associated with a worse clinical outcome. BJU Int. 2007 Nov; 100(5):1015-20.
    View in: PubMed
    Score: 0.048
  219. High-order interactions among genetic polymorphisms in nucleotide excision repair pathway genes and smoking in modulating bladder cancer risk. Carcinogenesis. 2007 Oct; 28(10):2160-5.
    View in: PubMed
    Score: 0.048
  220. A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study. J Urol. 2007 Jul; 178(1):68-73; discussion 73.
    View in: PubMed
    Score: 0.047
  221. Nomograms provide improved accuracy for predicting survival after radical cystectomy. Clin Cancer Res. 2006 Nov 15; 12(22):6663-76.
    View in: PubMed
    Score: 0.045
  222. Advanced age is associated with poorer bladder cancer-specific survival in patients treated with radical cystectomy. Eur Urol. 2007 Mar; 51(3):699-706; discussion 706-8.
    View in: PubMed
    Score: 0.045
  223. Characteristics and outcomes of patients with carcinoma in situ only at radical cystectomy. Urology. 2006 Sep; 68(3):538-42.
    View in: PubMed
    Score: 0.045
  224. Concomitant carcinoma in situ is a feature of aggressive disease in patients with organ-confined TCC at radical cystectomy. Eur Urol. 2007 Jan; 51(1):152-60.
    View in: PubMed
    Score: 0.045
  225. Discrepancy between clinical and pathologic stage: impact on prognosis after radical cystectomy. Eur Urol. 2007 Jan; 51(1):137-49; discussion 149-51.
    View in: PubMed
    Score: 0.044
  226. Clinical outcomes following radical cystectomy for primary nontransitional cell carcinoma of the bladder compared to transitional cell carcinoma of the bladder. J Urol. 2006 Jun; 175(6):2048-53; discussion 2053.
    View in: PubMed
    Score: 0.044
  227. Prostatic involvement by transitional cell carcinoma in patients with bladder cancer and its prognostic significance. Hum Pathol. 2006 Jun; 37(6):726-34.
    View in: PubMed
    Score: 0.044
  228. Cancer specific outcomes in patients with pT0 disease following radical cystectomy. J Urol. 2006 May; 175(5):1645-9; discussion 1649.
    View in: PubMed
    Score: 0.044
  229. Bladder cancer predisposition: a multigenic approach to DNA-repair and cell-cycle-control genes. Am J Hum Genet. 2006 Mar; 78(3):464-79.
    View in: PubMed
    Score: 0.043
  230. Lymphovascular invasion is independently associated with overall survival, cause-specific survival, and local and distant recurrence in patients with negative lymph nodes at radical cystectomy. J Clin Oncol. 2005 Sep 20; 23(27):6533-9.
    View in: PubMed
    Score: 0.042
  231. Polymorphisms in inflammation genes and bladder cancer: from initiation to recurrence, progression, and survival. J Clin Oncol. 2005 Aug 20; 23(24):5746-56.
    View in: PubMed
    Score: 0.042
  232. Polymorphisms in XPD exons 10 and 23 and bladder cancer risk. Cancer Epidemiol Biomarkers Prev. 2005 Apr; 14(4):878-84.
    View in: PubMed
    Score: 0.040
  233. Case-control analysis of dietary folate and risk of bladder cancer. Nutr Cancer. 2005; 53(2):144-51.
    View in: PubMed
    Score: 0.040
  234. Dietary carotenoids and genetic instability modify bladder cancer risk. J Nutr. 2004 Dec; 134(12):3362-9.
    View in: PubMed
    Score: 0.040
  235. Restoration of bone morphogenetic protein receptor type II expression leads to a decreased rate of tumor growth in bladder transitional cell carcinoma cell line TSU-Pr1. Cancer Res. 2004 Oct 15; 64(20):7355-60.
    View in: PubMed
    Score: 0.039
  236. Standardization of radical cystectomy and pelvic lymph node dissection for bladder cancer: a collaborative group report. J Urol. 2004 May; 171(5):1823-8; discussion 1827-8.
    View in: PubMed
    Score: 0.038
  237. Centrosomal abnormality is common in and a potential biomarker for bladder cancer. Int J Cancer. 2003 Sep 20; 106(5):661-5.
    View in: PubMed
    Score: 0.036
  238. Association of plasma urokinase-type plasminogen activator and its receptor with clinical outcome in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder. Urology. 2003 May; 61(5):1053-8.
    View in: PubMed
    Score: 0.035
  239. Bladder cancer screening program for a petrochemical cohort with potential exposure to beta-napthylamine. J Occup Environ Med. 2003 Mar; 45(3):289-94.
    View in: PubMed
    Score: 0.035
  240. Plasma levels of insulin-like growth factor-1 and binding protein-3, and their association with bladder cancer risk. J Urol. 2003 Feb; 169(2):714-7.
    View in: PubMed
    Score: 0.035
  241. Correlation of preoperative levels of IGF-I and IGFBP-3 with pathologic parameters and clinical outcome in patients with bladder cancer. Urology. 2003 Feb; 61(2):359-64.
    View in: PubMed
    Score: 0.035
  242. Preoperative plasma levels of transforming growth factor beta(1) strongly predict clinical outcome in patients with bladder carcinoma. Cancer. 2001 Dec 15; 92(12):2985-92.
    View in: PubMed
    Score: 0.032
  243. Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial. J Natl Cancer Inst. 2001 Apr 18; 93(8):597-604.
    View in: PubMed
    Score: 0.031
  244. The loss of expression of transforming growth factor-beta receptors correlates with the histopathologic tumor grade in bladder transitional cell carcinoma patients. Yonsei Med J. 1999 Apr; 40(2):118-23.
    View in: PubMed
    Score: 0.027
  245. Level of retinoblastoma protein expression correlates with p16 (MTS-1/INK4A/CDKN2) status in bladder cancer. Oncogene. 1999 Feb 04; 18(5):1197-203.
    View in: PubMed
    Score: 0.026
  246. Retinoids in the chemoprevention of bladder cancer. Curr Opin Oncol. 1998 Sep; 10(5):479-84.
    View in: PubMed
    Score: 0.026
  247. Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res. 1994 Feb 01; 54(3):784-8.
    View in: PubMed
    Score: 0.019
  248. Role of chromosome 9 in human bladder cancer. Cancer Res. 1993 Sep 01; 53(17):4066-70.
    View in: PubMed
    Score: 0.018
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.